TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $53.19, marking a -1.45% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.14%. At ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

Earlier in the week, ARK purchased 10,353 shares of CRISPR on Wednesday, valued at $584,530, and 43,333 shares on Tuesday, totaling $2,509,414. This consistent buying pattern suggests a strong ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

A single pill consisting of two or more medications may help improve outcomes in hypertension, according to a new American ...

Shares of CRISPR Therapeutics CRSP were up 3.7% yesterday after the company announced encouraging updates from ongoing ...

In summary, Cathie Wood’s ARK ETF made several significant trades today, including a notable reduction in Tesla holdings and strategic investments in Oklo and Rocket Lab. These moves reflect ARK’s ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.

According to Benzinga Pro, CRISPR Therapeutics AG's peer group average for short interest as a percentage of float is 14.28%, ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...